Pediatrix Medical Group (NYSE:MD) Stock Rating Upgraded by StockNews.com

Pediatrix Medical Group (NYSE:MD) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Wednesday.

MD has been the subject of a number of other reports. UBS Group lifted their price objective on Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Mizuho lifted their price target on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a report on Monday, November 4th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. Jefferies Financial Group boosted their target price on Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Finally, Truist Financial raised their price target on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a report on Monday, November 4th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $16.10.

Pediatrix Medical Group Price Performance

Shares of Pediatrix Medical Group stock opened at $14.74 on Wednesday. The firm has a market cap of $1.27 billion, a P/E ratio of -4.82, a price-to-earnings-growth ratio of 2.22 and a beta of 1.55. The firm’s 50-day simple moving average is $12.46 and its 200-day simple moving average is $9.81. Pediatrix Medical Group has a twelve month low of $6.62 and a twelve month high of $16.41. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The company had revenue of $511.20 million for the quarter, compared to the consensus estimate of $498.87 million. During the same period in the previous year, the business earned $0.29 earnings per share. The company’s quarterly revenue was up .9% on a year-over-year basis. As a group, research analysts expect that Pediatrix Medical Group will post 1.25 EPS for the current fiscal year.

Insider Buying and Selling

In other Pediatrix Medical Group news, CEO James D. Swift sold 11,100 shares of Pediatrix Medical Group stock in a transaction on Friday, August 30th. The shares were sold at an average price of $10.79, for a total transaction of $119,769.00. Following the completion of the sale, the chief executive officer now owns 170,001 shares of the company’s stock, valued at approximately $1,834,310.79. The trade was a 6.13 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Mary Ann E. Moore sold 8,108 shares of the stock in a transaction on Friday, November 8th. The shares were sold at an average price of $16.00, for a total value of $129,728.00. Following the completion of the transaction, the executive vice president now directly owns 135,810 shares in the company, valued at approximately $2,172,960. This trade represents a 5.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 53,808 shares of company stock worth $751,277 in the last quarter. Insiders own 2.00% of the company’s stock.

Institutional Investors Weigh In On Pediatrix Medical Group

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Pediatrix Medical Group by 3.8% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 237,708 shares of the company’s stock worth $2,755,000 after buying an additional 8,609 shares during the period. Rubric Capital Management LP boosted its stake in Pediatrix Medical Group by 1.5% during the 3rd quarter. Rubric Capital Management LP now owns 8,275,000 shares of the company’s stock worth $95,907,000 after acquiring an additional 125,000 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in Pediatrix Medical Group by 141.2% during the third quarter. BNP Paribas Financial Markets now owns 18,520 shares of the company’s stock valued at $215,000 after purchasing an additional 10,843 shares during the period. FMR LLC increased its stake in Pediatrix Medical Group by 220.6% in the third quarter. FMR LLC now owns 9,841 shares of the company’s stock valued at $114,000 after purchasing an additional 6,771 shares in the last quarter. Finally, Algert Global LLC acquired a new stake in Pediatrix Medical Group in the third quarter worth $1,315,000. Institutional investors own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.